The Neuropeptide Substance P is Elevated in Sickle Cell Disease and is a Marker of Severity of Vaso-occlusive Crisis
Main Article Content
Keywords
Neuropeptide Substance P, Sickle Cell Disease, Severity, Vaso-occlusive Crisis
Abstract
Background: Acute episode of pain is the most frequent symptom for which patients with sickle cell disease (SCD) seek medical attention. The neuropeptide Substance P (SP) has been suggested as a possible aetiologic factor. This study compared the serum levels of SP in SCD subjects in painful vaso-occlusive crisis with those in steady state and normal HbAA subjects.
Methodology: This case-controlled study investigated eighteen SCD patients in vaso-occlusive crisis (VOC) and eighteen in steady state, while fourteen HbAA subjects were recruited as controls. Blood was collected in plain bottles and subsequently, the serum was separated for SP assay using the ELISA technique. Each sample was run, and results were confirmed in duplicate. Optical density was read at an absorbance of 450nm.
Results: The study showed that SP was significantly higher in SCD patients in steady state (184.79±18.67ng/L versus 104.17±19.24ng/L) compared to the controls (t=2.97, p=0.006); while the values obtained in those in VOC (375.78±76.21ng/L) were also significantly higher (t=2.433, p=0.02) than those in steady state (184.79±18.67ng/L). The SP value in the SCD patients in VOC was almost twice as much as those in steady state and about three times as much as the value in the controls and the differences were statistically significant (t=7.72, p=0.001).
Conclusion: The study showed significantly higher SP levels in VOC compared to steady state or HbAA subjects suggesting that SP may be a marker for pain sensitisation.
References
2. World Health Organization Fifty-Ninth World Health Assembly A59/9, Provisional Agenda Item 11.4 24 April 2006.
3. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484.
4. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox‐Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol. 2004;77(4):323-328.
5. Makis A, Hatzimichael E, Bourantas K. The role of cytokines in sickle cell disease. Ann Hematol. 2000;79(8):407-413.
6. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on the production of inflammatory cytokines by human monocytes. Science. 1988;241:1218-1221.
7. Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120(5):744-752.
8. Kohli DR, Li Y, Khasabov SG, Gupta P, Kehl LJ, Ericson ME, et al. Pain-related behaviours and neurochemical alterations in mice expressing sickle haemoglobin: modulation by cannabinoids. Blood. 2010;116(3):456-465.
9. Ohaeri JU, Shokunbi WA. The psychosocial burden of sickle cell disease on caregivers in a Nigerian setting. J Natl Med Assoc. 2002;94(12):1058-1070.
10. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
11. Haines K, Kolasinski S, Cronstein B, Reibman J, Gold L, Weissmann G. Chemoattraction of neutrophils by substance P and transforming growth factor-beta 1 is inadequately explained by current models of lipid remodelling. J Immunol. 1993;151(3):1491-1499.
12. Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood. 1998;92(9):3148-3151.
13. Moussaoui S, Carruette A, Garret C. Further evidence is that substance P is a mediator of both neurogenic inflammation and pain: Two phenomena inhibited either by postsynaptic blockade of SP receptors or by presynaptic action of opiate agonists. Regul Neuropept. 1992;37:424-425.
14. Okayama Y, Ei-Lati SG, Leiferman KM, Church MK. Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells. J Aller Clin Immunol. 1994;93(5):900-909.
15. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on the production of inflammatory cytokines by human monocytes. Science. 1988;241:1218-1221.
16. Rameshwar P, Ganea D, Gascon P. In vitro stimulatory effect of substance P on hematopoiesis. Blood. 1993;81(2):391-398.
17. Serra M, Calzetti F, Ceska M, Cassatella M. Effect of substance P on superoxide anion and IL-8 production by human PMNL. Immunology. 1994;82(1):63-69.
18. Lee H, Ho W, Douglas S. Substance P augments tumor necrosis factor release in human monocyte-derived macrophages. Clin Diagn Lab Immunol. 1994;1(4):419-423.
19. Kish L. Survey Sampling. John Wiley and Sons. 1965:83.
20. Mabayoje V, Adeyemo M, Akinola N. Case Review: Drug addiction in sickle cell disease, a possible ongoing challenge in the management of pain? J Global Biosci. 2015;4(4): 2021-2025.
21. Duits A, Schnog J, Lard L, Saleh A, Rojer R. Elevated IL‐8 levels during sickle cell crisis. Eur J Haematol. 1998;61(5): 302-305.
22. Douglas SD. Substance P and sickle cell disease—a marker for pain and novel therapeutic approaches. Br J Haematol. 2016;175(2):187-188.
23. Brandow AM, Wandersee NJ, Dasgupta M, Hoffmann RG, Hillery CA, Stucky CL, et al. Substance P is increased in patients with sickle cell disease and is associated with haemolysis and hydroxycarbamide use. Br J Haematol. 2016;175(2):237-245.
24. Brandow AM, Stucky CL, Hillery CA, Hoffmann RG, Panepinto JA. Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol. 2013;88(1):37-43.
25. Vincent L, Vang D, Nguyen J, Gupta M, Luk K, Ericson ME, et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013;122(11):1853-1862.
26. Keikhaei B, Mohseni AR, Norouzirad R, Alinejadi M, Ghanbari S, Shiravi F, et al. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013;24(1):45-52.
27. Sarray S, Saleh LR, Saldanha FL, Al-Habboubi HH, Mahdi N, Almawi WYJC. Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady-state condition. Cytokine. 2015;72(1):43-47.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.